Early bleed detect Target hospitals and vascular and interventional cardiology programs performing high-risk endovascular procedures (TAVR, large bore MCS placements) where the Early Bird system addresses a critical safety need and can reduce complication-related costs.

Clinical trial momentum Leverage SAFE-MCS and ongoing FDA-cleared usage to position the system as a proven patient safety technology with expanding clinical evidence, offering sponsor-ready deployment kits and streamlined trial integration for customers exploring value-based care.

Regulatory trust Emphasize FDA-cleared status and real-world adoption (over 1,200 treated) to build credibility with procurement and clinical champions seeking validated innovation for vascular access risk reduction.

Strategic partnerships Engage with academic medical centers, cardio-thoracic surgeons, and interventional labs that perform complex PCI and MCS procedures, offering co-marketing, joint research, and bundled service contracts to accelerate adoption.

Growth signals Align with growth-stage investors and potential distributors in medical device ecosystems, highlighting the company’s funding history, scalable cloud-enabled monitoring, and a compact team focused on frontline safety tech to support channel-driven expansion.